Why the study?
Current therapies for AF remain ineffective largely because molecular mechanisms and atrial remodeling underlying AF are incompletely understood.
This review highlights the emerging role of noncoding RNAs in the pathogenesis, diagnosis, and potential treatment of atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Noncoding RNA strategies remain investigational in AF; leaves open their biomarker and therapeutic potential pending validation.
Atrial fibrillation (AF) is an important cause of cardiovascular morbidity and mortality. Current therapies for AF are ineffective, mainly due to incomplete understanding of the pathogenesis of AF. Atrial remodeling contributes to the occurrence and progression of AF, but molecular mechanisms underlying AF remain unclear. Noncoding RNAs, including microRNAs, long noncoding RNAs and circular RNAs, are now considered to play an important role in the pathophysiology of AF. In this review, we summarize recent evidence supporting the role of noncoding RNAs in AF and highlight their diagnostic and prognostic applications as potential biomarkers and therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: